Lilly Pre-Approval Spadework Includes Alzheimer’s Blood Test Development, Unbranded DTC Ads
Lilly is supporting development of blood-based tools for early diagnose of Alzheimer's, but the delay of the review for donanemab will create more distance from Lilly’s direct-to-consumer advertising spotlighting its commitment to Alzheimer’s research.
